Compare UBFO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBFO | CHRS |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.7M | 186.0M |
| IPO Year | 2001 | 2014 |
| Metric | UBFO | CHRS |
|---|---|---|
| Price | $10.36 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 14.7K | ★ 1.7M |
| Earning Date | 04-23-2026 | 06-01-2026 |
| Dividend Yield | ★ 4.66% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | 0.51 | ★ 1.43 |
| Revenue | ★ $2,918,000.00 | N/A |
| Revenue This Year | N/A | $88.67 |
| Revenue Next Year | N/A | $28.64 |
| P/E Ratio | $20.24 | ★ $1.36 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.32 | $0.72 |
| 52 Week High | $11.52 | $2.62 |
| Indicator | UBFO | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 38.44 | 52.43 |
| Support Level | $8.31 | $1.55 |
| Resistance Level | $10.53 | $1.89 |
| Average True Range (ATR) | 0.26 | 0.10 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 16.35 | 59.30 |
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.